Sangamo Biosciences (SGMO) 12.98 $SGMO
Sickle Cell Disease - Pipeline Review, H1 2014: Includes 24 Company and 39 Drug Profiles
M2 - Mon May 12, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxjscz/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics - Advinus Therapeutics Ltd. - AesRx, LLC - Alnylam Pharmaceuticals, Inc. - Archemix Corp. - Astellas Pharma Inc. - Cellerant Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Johnson & Johnson - Mast Therapeutics, Inc. - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - OrphageniX, Inc. - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - SynZyme Technologies, LLC Drug Profiles: - prasugrel hydrochloride - glutamine - magnesium sulfate - vepoloxamer - Aes-103 - regadenoson - montelukast sodium [hydroxyurea] - LentiGlobin - NiCord - panobinostat - zileuton CR - sevuparin sodium - Sanguinate - tetrahydrouridine [decitabine] - NKTT-120 - CNTO-530 - Enhoxy - Trichostatin A - Aptamer To Inhibit P-Selectin For Sickle Cell Disease - ZFP Transcription Factors for Hemoglobinopathies - DNA Oligonucleotides For Sickle Cell Anemia - VBP-15 - PNQ-103 - Gene Therapy for Sickle Cell Disease - ALN-TMP - Lentiviral-Mediated Gene Therapy - AIC-6020 - ACY-957 - VitalHeme - EdX-17 For more information visit http://www.researchandmarkets.com/research/cx...ickle_cell
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Downtrend Call Working As Sangamo Biosciences Stock Falls 38.1% (SGMO)
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 1 month, Sangamo Biosciences has returned 38.11% as of today's recent price of $11.80.
Why Sangamo Biosciences Inc. Shares Slumped
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 2:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sangamo Biosciences , a clinical-stage...
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Sangamo BioSciences Reports First Quarter 2014 Financial Results
PR Newswire - Tue May 06, 3:02PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments.
Sangamo Biosciences (SGMO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:09AM CDT
Sangamo Biosciences (SGMO) Enters Oversold Territory
Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
PR Newswire - Thu May 01, 3:05PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at the following investor conferences:
27.4% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Wed Apr 30, 4:41PM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 1 month, Sangamo Biosciences has returned 27.41% as of today's recent price of $13.84.
Sangamo BioSciences Announces First Quarter 2014 Conference Call And Webcast
PR Newswire - Tue Apr 29, 3:05PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2014 financial results on Tuesday, May 6, 2014, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.
Sangamo Biosciences Has Returned 26.1% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 23, 10:58AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 4 weeks, Sangamo Biosciences has returned 26.09% as of today's recent price of $14.09.
Insider Trading Alert - SPLK, SGMO And CMLP Traded By Insiders
at The Street - Mon Apr 21, 10:00AM CDT
Stocks with insider trader activity include SPLK, SGMO and CMLP
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
'Mad Money' Lightning Round: I Don't See a BioMarin Rally
at The Street - Fri Apr 11, 5:00AM CDT
Cramer likes Service Corp. over Carriage Services and Magnum Hunter Resources over Swift Energy.
Jim Cramer's 'Mad Money' Recap: Blame China, Greece for the Meltdown
at The Street - Thu Apr 10, 7:24PM CDT
While everything went right in America, everything was going wrong in the rest of the world -- and that apparently makes all the difference, Cramer says.
Sangamo Biosciences Has Returned 17.0% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 09, 9:10AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 2 weeks, Sangamo Biosciences has returned 17.03% as of today's recent price of $15.82.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Sangamo Biosciences Has Returned 91.4% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Tue Mar 25, 9:09AM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on November 18th, 2013 at $10.38. In approximately 4 months, Sangamo Biosciences has returned 91.42% as of today's recent price of $19.86.
Sickle Cell Disease - Pipeline Review, H1 2014: Includes 24 Company and 39 Drug Profiles
M2 - Mon May 12, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxjscz/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics - Advinus Therapeutics Ltd. - AesRx, LLC - Alnylam Pharmaceuticals, Inc. - Archemix Corp. - Astellas Pharma Inc. - Cellerant Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Johnson & Johnson - Mast Therapeutics, Inc. - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - OrphageniX, Inc. - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - SynZyme Technologies, LLC Drug Profiles: - prasugrel hydrochloride - glutamine - magnesium sulfate - vepoloxamer - Aes-103 - regadenoson - montelukast sodium [hydroxyurea] - LentiGlobin - NiCord - panobinostat - zileuton CR - sevuparin sodium - Sanguinate - tetrahydrouridine [decitabine] - NKTT-120 - CNTO-530 - Enhoxy - Trichostatin A - Aptamer To Inhibit P-Selectin For Sickle Cell Disease - ZFP Transcription Factors for Hemoglobinopathies - DNA Oligonucleotides For Sickle Cell Anemia - VBP-15 - PNQ-103 - Gene Therapy for Sickle Cell Disease - ALN-TMP - Lentiviral-Mediated Gene Therapy - AIC-6020 - ACY-957 - VitalHeme - EdX-17 For more information visit http://www.researchandmarkets.com/research/cx...ickle_cell
Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Downtrend Call Working As Sangamo Biosciences Stock Falls 38.1% (SGMO)
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 1 month, Sangamo Biosciences has returned 38.11% as of today's recent price of $11.80.
Why Sangamo Biosciences Inc. Shares Slumped
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 2:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sangamo Biosciences , a clinical-stage...
Global Hemophilia A Therapeutics Pipeline Review 2014
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7x7lg3/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - Grifols, S.A. - BioMarin Pharmaceutical Inc. - Chugai Pharmaceutical Co., Ltd. - rEVO Biologics - Octapharma AG - Pfizer Inc. - Bayer AG - Prolor Biotech, Inc. - ReGenX Biosciences, LLC - Alnylam Pharmaceuticals, Inc. - CSL Limited - Green Cross Corporation - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - Inserm Transfert SA - Selecta Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - Inbiopro Solutions Pvt. Ltd. - International Biotechnology Center Generium - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/7x...mophilia_a
Sangamo BioSciences Reports First Quarter 2014 Financial Results
PR Newswire - Tue May 06, 3:02PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments.
Sangamo Biosciences (SGMO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:09AM CDT
Sangamo Biosciences (SGMO) Enters Oversold Territory
Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
PR Newswire - Thu May 01, 3:05PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at the following investor conferences:
27.4% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Wed Apr 30, 4:41PM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 1 month, Sangamo Biosciences has returned 27.41% as of today's recent price of $13.84.
Sangamo BioSciences Announces First Quarter 2014 Conference Call And Webcast
PR Newswire - Tue Apr 29, 3:05PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2014 financial results on Tuesday, May 6, 2014, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.
Sangamo Biosciences Has Returned 26.1% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 23, 10:58AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 4 weeks, Sangamo Biosciences has returned 26.09% as of today's recent price of $14.09.
Insider Trading Alert - SPLK, SGMO And CMLP Traded By Insiders
at The Street - Mon Apr 21, 10:00AM CDT
Stocks with insider trader activity include SPLK, SGMO and CMLP
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
'Mad Money' Lightning Round: I Don't See a BioMarin Rally
at The Street - Fri Apr 11, 5:00AM CDT
Cramer likes Service Corp. over Carriage Services and Magnum Hunter Resources over Swift Energy.
Jim Cramer's 'Mad Money' Recap: Blame China, Greece for the Meltdown
at The Street - Thu Apr 10, 7:24PM CDT
While everything went right in America, everything was going wrong in the rest of the world -- and that apparently makes all the difference, Cramer says.
Sangamo Biosciences Has Returned 17.0% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Wed Apr 09, 9:10AM CDT
SmarTrend identified a Downtrend for Sangamo Biosciences (NASDAQ:SGMO) on March 25th, 2014 at $19.07. In approximately 2 weeks, Sangamo Biosciences has returned 17.03% as of today's recent price of $15.82.
Top Gainers Updates -- Research on Sangamo BioSciences, Synthesis Energy Systems, OXiGENE, and Affymetrix
PR Newswire - Tue Apr 01, 8:08AM CDT
On Monday, March 31, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,198.99, up 1.04%, the Dow Jones Industrial Average ended the session at 16,457.66, up 0.82% and the S&P 500 edged 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Sangamo BioSciences Inc. (NASDAQ: SGMO), Synthesis Energy Systems Inc. (NASDAQ: SYMX), OXiGENE Inc. (NASDAQ: OXGN) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on SGMO, SYMX, OXGN and AFFX can be downloaded upon signing up at:
Sangamo Biosciences Has Returned 91.4% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Tue Mar 25, 9:09AM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on November 18th, 2013 at $10.38. In approximately 4 months, Sangamo Biosciences has returned 91.42% as of today's recent price of $19.86.
